Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

ClinicalTrials.gov ID: NCT00289783

Public ClinicalTrials.gov record NCT00289783. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 12:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.

Study identification

NCT ID
NCT00289783
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
4,441 participants

Conditions and interventions

Interventions

  • GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine Biological
  • ActHIB Biological
  • PedvaxHIB Biological
  • Pediarix Biological
  • Prevnar Biological
  • M-M-R II Biological
  • Varivax Biological

Biological

Eligibility (public fields only)

Age range
6 Weeks to 15 Months
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 21, 2006
Primary completion
Aug 26, 2007
Completion
Feb 25, 2008
Last update posted
Aug 23, 2018

2006 – 2008

United States locations

U.S. sites
88
U.S. states
31
U.S. cities
79
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35216
GSK Investigational Site Birmingham Alabama 35235
GSK Investigational Site Phoenix Arizona 85003
GSK Investigational Site Bryant Arkansas 72011
GSK Investigational Site Fayetteville Arkansas 72703
GSK Investigational Site Little Rock Arkansas 72202
GSK Investigational Site Little Rock Arkansas 72205
GSK Investigational Site East Artesia California 90706
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Fresno California 93710
GSK Investigational Site Fresno California 93720
GSK Investigational Site Fresno California 93726
GSK Investigational Site La Jolla California 92037
GSK Investigational Site Oakland California 94609
GSK Investigational Site Paramount California 90723
GSK Investigational Site Rolling Hills Estates California 90274
GSK Investigational Site Sacramento California 95817
GSK Investigational Site West Covina California 91790
GSK Investigational Site Longmont Colorado 80501
GSK Investigational Site Norwich Connecticut 06360
GSK Investigational Site Cocoa Beach Florida 32931
GSK Investigational Site Melbourne Florida 332901
GSK Investigational Site Pembroke Pines Florida 33024
GSK Investigational Site Rockledge Florida 32955
GSK Investigational Site Nampa Idaho 208 463 3126
GSK Investigational Site Des Moines Iowa 50266
GSK Investigational Site Des Moines Iowa 50309
GSK Investigational Site Arkansas City Kansas 67005
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site Bardstown Kentucky 40004
GSK Investigational Site Lexington Kentucky 40503
GSK Investigational Site Louisville Kentucky 40272
GSK Investigational Site Bossier City Louisiana 71111
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site Boston Massachusetts 02118
GSK Investigational Site Fall River Massachusetts 02724
GSK Investigational Site Jamaica Plain Massachusetts 02130
GSK Investigational Site Kalamazoo Michigan 49008
GSK Investigational Site Portage Michigan 49024
GSK Investigational Site Stevensville Michigan 49127
GSK Investigational Site Brainerd Minnesota 56401
GSK Investigational Site Saint Paul Minnesota 55108
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site North Las Vegas Nevada 89025
GSK Investigational Site Ithaca New York 14850
GSK Investigational Site New Hartford New York 13413
GSK Investigational Site Rochester New York 14618
GSK Investigational Site Stony Brook New York 11794
GSK Investigational Site Syracuse New York 13210
GSK Investigational Site The Bronx New York 10467
GSK Investigational Site Durham North Carolina 27705
GSK Investigational Site Durham North Carolina 27710
GSK Investigational Site Raleigh North Carolina 27609
GSK Investigational Site Sylva North Carolina 28779
GSK Investigational Site Boardman Ohio 44512
GSK Investigational Site Canton Ohio 44718
GSK Investigational Site Cleveland Ohio 44121
GSK Investigational Site Columbus Ohio 43205
GSK Investigational Site Huber Heights Ohio 45424
GSK Investigational Site South Euclid Ohio 44121
GSK Investigational Site Tulsa Oklahoma 74127
GSK Investigational Site Gresham Oregon 97030
GSK Investigational Site Beaver Falls Pennsylvania 15010
GSK Investigational Site Erie Pennsylvania 16501
GSK Investigational Site Greenville Pennsylvania 16125
GSK Investigational Site Hershey Pennsylvania 17033-0850
GSK Investigational Site Philadelphia Pennsylvania 19114
GSK Investigational Site Pittsburgh Pennsylvania 15212
GSK Investigational Site Pittsburgh Pennsylvania 15213
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Pittsburgh Pennsylvania 15241
GSK Investigational Site Sellersville Pennsylvania 18960
GSK Investigational Site Providence Rhode Island 02903
GSK Investigational Site Charleston South Carolina 29406
GSK Investigational Site Lexington South Carolina 29072
GSK Investigational Site Amarillo Texas 79124
GSK Investigational Site Fort Worth Texas 76107
GSK Investigational Site Galveston Texas 77555-0188
GSK Investigational Site San Antonio Texas 78205
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Layton Utah 84041
GSK Investigational Site Pleasant Grove Utah 84062
GSK Investigational Site South Jordan Utah 84095
GSK Investigational Site St. George Utah 84790
GSK Investigational Site Mechanicsville Virginia 23111
GSK Investigational Site Norfolk Virginia 23510
GSK Investigational Site Vancouver Washington 98664
GSK Investigational Site La Crosse Wisconsin 54601

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00289783, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 23, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00289783 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →